Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 4,638,095 | 4,479,624 | 4,442,678 | 4,806,824 | 5,622,408 |
| Marketable Securities | 117,233 | 171,431 | 157,704 | 293,832 | 146,102 |
| Receivables | 10,695,110 | 10,231,790 | 11,192,960 | 10,280,110 | 9,447,510 |
| Inventories | 8,296,558 | 7,811,979 | 8,246,452 | 8,109,763 | 7,557,000 |
| Other current assets | 185,955 | 395,616 | 9,436 | 113,531 | 5,040 |
| TOTAL | $23,932,950 | $23,090,440 | $24,049,230 | $23,604,060 | $22,778,060 |
| Non-Current Assets | |||||
| PPE Net | 12,585,650 | 12,292,920 | 12,592,080 | 12,178,000 | 11,529,460 |
| Investments And Advances | 1,316,507 | 1,484,856 | 1,459,776 | 1,304,881 | 1,299,804 |
| Intangibles | 34,260,192 | 31,340,227 | 32,325,334 | 29,530,121 | 29,200,247 |
| Other Non-Current Assets | 12,620,681 | 12,387,867 | 12,252,420 | 12,527,928 | 11,650,379 |
| TOTAL | $60,783,030 | $57,505,870 | $58,629,610 | $55,540,930 | $53,679,890 |
| Total Assets | $84,715,980 | $80,596,300 | $82,678,840 | $79,144,980 | $76,457,950 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 6,796,790 | 3,971,924 | 3,849,602 | 2,737,980 | 2,466,101 |
| Accounts payable and accrued liabilities | 19,316,410 | 20,282,920 | 21,128,330 | 19,793,590 | 19,080,170 |
| Accrued Expenses | 747,863 | 656,713 | 436,720 | 775,984 | 790,966 |
| Other current liabilities | 3,362,012 | 3,296,750 | 3,341,444 | 3,909,301 | 3,899,412 |
| TOTAL | $30,223,080 | $28,208,310 | $28,756,100 | $27,216,860 | $26,236,640 |
| Non-Current Liabilities | |||||
| Long Term Debt | 18,881,170 | 19,395,440 | 20,075,620 | 20,440,020 | 20,749,000 |
| Other Non-Current Liabilities | 11,604,665 | 11,446,131 | 11,912,744 | 11,532,913 | 11,579,846 |
| TOTAL | $31,016,750 | $31,346,820 | $32,690,620 | $32,756,930 | $33,024,090 |
| Total Liabilities | $61,239,830 | $59,555,130 | $61,446,720 | $59,973,780 | $59,260,730 |
| Shareholders' Equity | |||||
| Common Shares | 1,817,777 | 1,778,926 | 1,818,317 | 1,801,724 | 1,699,066 |
| Retained earnings | 15,617,530 | 13,462,610 | 13,500,570 | 11,749,270 | 10,462,670 |
| Other shareholders' equity | 1,316,498 | 1,186,831 | 1,214,454 | 964,305 | 647,376 |
| TOTAL | $23,476,140 | $21,041,180 | $21,232,120 | $19,171,200 | $17,197,210 |
| Total Liabilities And Equity | $84,715,970 | $80,596,310 | $82,678,840 | $79,144,980 | $76,457,940 |